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Edited by Jacomine Krijnse-LockerAbstract SAMMA, a mandelic acid condensation polymer,
exhibits a broad antimicrobial activity against several sexually
transmitted pathogens including human immunodeﬁciency virus
(HIV). Here we demonstrated that SAMMA suppressed HIV
transmission by dendritic cells (DCs), one of the ﬁrst target cells
for primary infection. The greatest inhibitory eﬀect was achieved
when SAMMA was present during the co-culture with target
cells. The inhibitory eﬀect of SAMMA on DC-mediated HIV
transmission was not due to cytotoxicity. Analysis of the level
of DC-associated HIV p24 antigen revealed that SAMMA pre-
vented HIV internalization by DCs when the virus was pre-incu-
bated with the compound. In contrast, pre-incubation of DCs
with SAMMA followed by wash-oﬀ did not aﬀect the amount
of cell-associated HIV p24 antigen. In addition, SAMMA
blocked HIV glycoprotein-mediated cell–cell fusion. This study
suggests that SAMMA prevents HIV infection through multiple
mechanisms.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cell–cell fusion; Non-sulfonated polyanions1. Introduction
Sexual transmission is the most common route of acquiring
human immunodeﬁciency virus (HIV). Women account for
nearly half of those infected worldwide and more than 70% in
sub-Saharan Africa (UNAIDS report 2006). Women are more
susceptible to HIV because of a higher prevalence of sexual
transmitted infections (STIs) in addition to hormone changes
[1,2]. As an eﬀective vaccine against HIV infection is unlikely
to be available in the near future, development of a safe and
eﬀective topical microbicide to prevent sexual transmission of
HIV as well as other STIs becomes an urgent need. Indeed,
studies in rhesus macaques support the concept that topical
microbicides can prevent vaginal virus transmission [3–5].Abbreviations: HIV, human immunodeﬁciency virus; DC, dendritic
cells; LTR, long terminal repeat
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doi:10.1016/j.febslet.2007.08.048Dendritic cells (DCs) present in the vaginal epithelium and
lamina propria, are one of the ﬁrst target cells for primary
infection with simian immunodeﬁciency virus (SIV) and HIV
[6–8]. DCs can capture HIV and present it to CD4+ T cells
eﬃciently in vitro, suggesting that genital mucosa DCs may
uptake and transmit HIV to the surrounding CD4+ T cells
or to the draining lymph nodes [6–11]. HIV can establish
infection by binding to CD4, mannose-binding C-type lectin
receptor (MCLR), other MCLR like mannose receptor, and
non-MCLRs on the surface of diﬀerent subsets of DCs [12–16].
Therefore, it would be an important feature for an ideal topical
microbicide to block DC-mediated HIV transmission.
SAMMA, a mandelic acid condensation polymer, has been
shown to be a potential candidate as topical microbicide.
SAMMA, a non-sulfonated polyanion, diﬀers from N-9 (a
detergent) or cellular sulfate (sulfonated polyanion), two
microbicide candidates in clinical trials that not only failed
to prevent but also enhanced HIV transmission in women
([17–19] and aidsinfo.nih.gov). It exhibits potent anti-HIV
activity in vitro by interacting with HIV gp120 at a high aﬃn-
ity and subsequently blocking HIV entry [20,21]. Importantly,
it also inhibits other sexually transmitted pathogens including
herpes simplex viruses (HSV) 1 and 2, Chlamydia trachomatis,
and Neisseria gonorrhoeae [20,22] that are associated with HIV
enhancement [23–27]. In addition, SAMMA does not cause
cytotoxicity in mammalian cells or aﬀect the growth of com-
mensal bacteria such as lactobacilli [22].
Here we evaluated the eﬀect of SAMMA on DC-mediated
HIV transmission. We demonstrated that SAMMA inhibited
HIV capture and transfer by DCs as well as HIV glycopro-
tein-mediated cell–cell fusion. This study demonstrates that
SAMMA can block HIV infection by interfering with HIV
interaction with not only CD4 but also other receptors on var-
ious target cells, suggesting utilization of multiple mechanisms
for HIV prevention.2. Materials and methods
2.1. DC preparation and cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque gradient centrifugation. CD14+ monocytes were
positively selected from PBMCs using CD14+ magnetic beads from
Miltenyi Biotec, Inc. (Auburn, CA). Monocyte derived dendritic cells
(MDDCs) were obtained by culturing CD14+ monocytes in the pres-blished by Elsevier B.V. All rights reserved.
T.L. Chang et al. / FEBS Letters 581 (2007) 4596–4602 4597ence of IL-4 (100 U/ml, R&D Systems) and GM-CSF (1000 U/ml,
R&D systems) for 6–7 days and cytokines were added every other
day. This DC population has a CD14, CD11c+, HLA-DR+, CD3,
and CD83 phenotype. Autologus CD4+ T cells were treated with
phytohemagglutinin (PHA) at 5 lg/ml for 48–72 h and subsequently
cultured in complete RPMI with 10% fetal bovine serum (FBS) and
supplemented with IL-2 at a concentration of 20–50 U/ml.
2.2. DC-mediated HIV transmission
To study DC-mediated HIV transmission, DCs were exposed to R5
strain HIVBaL or pseudotyped HIVJR-FL luciferase reporter virus in the
presence or absence of SAMMA. Peseudotyped HIVJR-FL luciferase
reporter virus was prepared as described previously [28]. After washing
oﬀ, DCs were co-cultured with susceptible cells including PHA-acti-
vated primary CD4+ cells or HeLa-CD4.CCR5 cells. HIV p24 levels
in the media were measured by ELISA (SAIC-Frederick Inc.) for a
multiple-round infection assay, whereas luciferase activity in target
cells was determined by a single-infection assay as described previously
[29].
2.3. Cytotoxicity assay
DCs, activated primary CD4+ T cells, or TZM-bl cells at 2–5 · 104
in a 96-well plate were treated with SAMMA at indicated concentra-
tions for 2 h or three days at 37 C. Cytotoxicity was determined by
measuring the number of viable cells by the MTS assay (CellTiter 96
AQueous Non-Radioactive Cell Proliferation Assay, Promega, Inc.)
according to manufacture’s instructions. MTS substrate was added
to cells and cells were incubated at 37 C for 1 h. The conversion of
MTS into soluble formazan by dehydrogenase enzymes found in met-
abolically active cells was measured by quantifying of formazan prod-
ucts using absorbance at 490 nm in a microplate reader.
2.4. HIV capture
HIV-1 capture assay was performed as described elsewhere with
modiﬁcations [30]. MDDCs were seeded at 2 · 105 per well in 96-well
ﬂat-bottom plates. HIV-1BaL (3 ng per well) was pre-incubated in the
absence or presence of SAMMA for 1 h at 37 C. DCs were then incu-
bated with virus for 2 h at 4 C (for binding) or 37 C (for binding and
internalization). Cells were washed four times to remove unbound
virus and SAMMA and lysed with 1% Triton X-100. Cell-associated
HIV p24 antigen was measured by p24 ELISA (NCI, Frederick).
To determine whether SAMMA interacted with cellular receptors on
DCs and subsequently aﬀected HIV capture, DCs were pre-incubated
with SAMMA at 37 C for 1 h, washed four times with PBS before
HIV exposure at 4 C or 37 C for 2 h. Cells were washed four times
and the level of cell-associated HIV p24 antigen was measured by ELI-
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Fig. 1. SAMMA inhibits HIV transmission by DCs. (a) MDDCs (1.25–2 · 1
MOI of 0.002 in the presence or absence of SAMMA at 100 lg/ml at 37 C
primary CD4+ T cells (1 · 106) in complete media in the presence or absen
(control) or with SAMMA at 100 lg/ml at 37 C for 1 h followed by additio
After washing four times with media, DCs (1.25 · 105) were incubated with ac
released into media was monitored by measuring the level of HIV p24 antig
duplicated samples and represent two independent experiments. In the wash2.5. HIV glycoprotein-mediated cell–cell fusion
HeLa cells expressing Tat protein (HeLa-Tat) were transfected with
the HIVJR-FL envelope plasmid (gift of D. Littman, New York Univer-
sity) for 48 h. HeLa-Tat cells at 5 · 105 expressing HIV glycorpoteins
were treated with SAMMA or T-20 (from ARRRP) at 37 C for 1 h
before addition to TZM-bl indicator cells (from ARRRP; gift of
Drs. J.C. Kappes, and X. Wu), which express CD4, CXCR4 and
CCR5 co-receptors. TZM-bl cells, seeded at 5 · 105 per well in a 48-
well plate, contain HIV long terminal repeat (LTR)-driven beta galac-
tosidase and luciferase reporter genes. When cell–cell fusion occurs,
Tat proteins activate these reporter genes. After incubation for 8–
24 h at 37 C, TZM-bl cells were treated with lysis buﬀer (Promega
Corp.) and luciferase activity (in relative light units [RLUs]) was mea-
sured using Perkin–Elmer 1420 Luminometer.3. Results
3.1. SAMMA blocked HIV transmission by DCs
Both intraepithelial and submucosal DCs and CD4+ T cells
are the primary target cell populations for SIV and HIV-1 (re-
viewed in [6,8]). It has been shown that SAMMA at 100 lg/ml
inhibits HIV infection (greater than 90%) in primary CD4+ T
cells [20]. Here we investigated the eﬀect of SAMMA on
HIV-1 transmission by DCs. Human monocyte derived DCs
(MDDCs) were exposed to replication-competent R5 virus
HIVBaL in the presence or absence of SAMMA at 100 lg/ml
for 2 h. An HIV-1 R5 strain was used as these strains are
preferentially transmitted in primary infection [31]. DCs were
washed and then co-cultured with autologous PHA-activated
primary CD4+ T cells in the presence or absence of SAMMA
at 100 lg/ml. HIV-1 infection was monitored by measuring the
level of HIV p24 antigen in the media by ELISA. DCs in the
absence of CD4+ T cells produced little virus (7 ng/ml at days
9 and 14 after infection, data not shown) in comparison to
DC-T cell co-culture that produced 800–1200 ng/ml (Fig. 1a,
control). SAMMA blocked DC-mediated HIV transmission
by greater than 99% when it was present during the all co-cul-
ture period (Fig. 1a).
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cells. An experiment was set up to simulate a possible in vivo
scenario when SAMMA would be present only during HIV
capture by DCs but absent during HIV transfer to CD4+ T
in draining lymph nodes. HIV-1BaL was ﬁrst exposed to SAM-
MA for 1 h followed by incubation with DCs for 2 h to allow
HIV capture. DCs were then washed extensively before co-cul-
turing with activated primary CD4+ T cells. In wash-oﬀ set-
tings, SAMMA at 100 lg/ml inhibited HIV transmission by
50–90% at day 9 after infection depending on the donors
(Fig. 1b). In addition, we observed the lack of increase in the
level of p24 at day 14 after infection, suggesting residual SAM-
MA and or persistent eﬀect of SAMMA on the cell after wash-
ing oﬀ. Taken together, results in Fig. 1 suggest that SAMMA
can block HIV transmission in vaginal/cervical mucosa but its
maximal eﬀect is when it is present both for DC capture and T
cell transfer.
To determine the eﬀect of SAMMA on HIV transmission in
trans, we used a replication-defective R5 strain HIVJR-FL
pseudotyped virus containing a luciferase reporter gene to
measure HIV transfer by DCs to target cells. Expression of
luciferase provides a quantitative measure of a single-round
of HIV infection [32]. MDDCs, capturing HIV primarily
through MCLRs [33], were incubated with SAMMA, anti-
DC-SIGN antibody, or mannose receptor ligand mannan,
which blocks gp120 binding to C-type lectins [34], for 1 h fol-
lowed by exposure to viruses for 2 h in the absence or presence
of inhibitors or antibodies (Fig. 2a). Although CD4 is not the
predominant receptor on MDDCs for the binding of HIV
gp120 [33], DCs were also treated with anti-CD4 antibody in
comparison to SAMMA (Fig. 2b). After 2 h incubation with
HIV, DCs were extensively washed then added to HeLa cells
expressing CD4 and CCR5, which provided a better luciferase
read-out in comparison to primary CD4+ T cells. After incuba-
tion for 48 h, HIV transfer to HeLa-CD4. CCR5 cells was
determined by measuring luciferase activity in the cells. SAM-
MA at 100 lg/ml eﬀectively inhibited HIV transmission bymannan (mg/ml)
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Fig. 2. SAMMA inhibits HIV infection in trans by DCs in a single-round
(100 lg/ml), mannan (0.1 and 5 mg/ml) or anti-DC-SIGN antibody (20 lg/m
pseudotyped HIVJR-FL luciferase reporter virus for 2 h at 37 C. Cells were
48 h. DCs were removed by washing and luciferase activity in relative light u
SAMMA at 100 lg/ml, anti-CD4 antibody (10 lg/ml, Leu3a from BD Biosci
followed by exposure to pseudotyped HIVJR-FL luciferase reporter virus for 2
for 48 h before measurement of luciferase activity in HeLa cells. (c) DCs wer
37 C and then incubated without or with SAMMA at 100 lg/ml for 1 h at 3
HeLa-CD4.CCR5 cells in the absence (wash-oﬀ) or presence (add back) of S
are means ± SD of triplicated samples and represent three independent expeDCs when it was present only during exposure of DCs to virus
in a single-cycle infection assay (Fig. 2a and b). As expected,
mannan inhibited the ability of DCs to transmit HIV. In agree-
ment with previous reports [30,33,35], anti-DC-SIGN anti-
body partially blocked HIV transmission by DCs, although
it completely blocked HIV transmission by a cell line express-
ing DC-SIGN by greater than 95% (data not shown). No eﬀect
was observed in samples treated with isotyped control antibod-
ies (Fig. 2b). Anti-CD4 antibody (Leu3a) at 10 lg/ml, which
inhibited HIV infection in activated primary CD4+ T cells
(data not shown), did not block DC-mediated HIV transmis-
sion when it was present during HIV capture by DCs (Fig. 2b).
We then assessed whether SAMMA could inhibit HIV trans-
mission when added after DCs were exposed to HIV. MDDCs
were exposed to HIV followed by incubation with SAMMA.
The inhibitor was washed away before co-culture of DCs with
target cells. SAMMA blocked HIV transmission in the wash-
oﬀ setting (Fig. 2c). The inhibitory eﬀect of SAMMA on
HIV transmission by HIV-exposed DCs was similar when
the inhibitor was present during the co-culture (add back) in
a single-cycle infection assay.
3.2. SAMMA is not cytotoxic to DCs
To ensure that the inhibitory eﬀect of SAMMA on DC-med-
iated HIV transmission was not due to cytotoxicity, we exam-
ined viability of DCs and CD4+ T cells in the presence of
SAMMA by MTS assay. SAMMA had no eﬀect on the viabil-
ity of DCs or CD4+ T cells when present in the culture for
three days at the dose up to 500 lg/ml, indicating that inhibi-
tion of DC-mediated HIV transmission was not associated
with cytotoxicity (Fig. 3).
3.3. SAMMA blocked DC-mediated HIV capture
The ability of SAMMA to block DC-mediated HIV trans-
mission when it was present only during the initial exposure
of DCs to HIV suggests that SAMMA may interfere with
HIV capture by DCs. To determine the eﬀect of SAMMAControl SAMMA SAMMA
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infection assay. (a) MDDCs (1 · 106) were incubated with SAMMA
l, mAb 612 from R&D systems) for 1 h at 37 C and then exposed to
washed four times before co-culturing with HeLa-CD4.CCR5 cells for
nit (RLU) in HeLa cells were measured. (b) DCs were incubated with
ences) or an isotype control antibody (mouse IgG1, j) at 37 C for 1 h
h. DCs were washed and then co-cultured with HeLa-CD4.CCR5 cells
e exposed to pseudotyped HIVJR-FL luciferase reporter virus for 2 h at
7 C. DCs were washed four times with PBS and then co-cultured with
AMMA for 48 h. Luciferase activity in HeLa cells was measured. Data
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Fig. 3. SAMMA does not cause cytotoxicity in DCs and primary
CD4+ T cells. DCs or activated primary CD4+ T cells (5 · 104) were
treated with SAMMA at 10, 100, 500 lg/ml for three days at 37 C.
Cytotoxicity was determined by measuring the number of viable cells
by the MTS assay (Promega). MTS substrate was added to cells for 1 h
at 37 C. Data are means ± SD of triplicated samples and represent
two independent experiments.
T.L. Chang et al. / FEBS Letters 581 (2007) 4596–4602 4599on HIV capture by DCs, HIV-1BaL was incubated in the ab-
sence (control) or presence of SAMMA at 100 lg/ml for 1 h0
1
2
3
4
5
6
7
p2
4 
ng
/m
l
Donor 1
control SAMMA
a
b
0
0.05
0.1
0.15
0.2
0.25
0.3
p2
4 
ng
/m
l
Control SAMMA
4 oC
37 oC
Fig. 4. SAMMA inhibits HIV capture by DCs. MDDC were seeded at 2 · 1
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100. Cell-associated HIV p24 antigens were measured by p24 ELISA (NCI,
from two donors are shown. In (b), results represent two independent expe
(control) or with SAMMA at 100 lg/ml at 37 C for 1 h and washed four tim
washed and lysed. Cell-associated HIV p24 antigen was measured by ELISAat 37 C before exposure to DCs for 2 h at 37 C (for viral
binding and internalization, Fig. 4a) or 4 C (viral binding
only, Fig. 4b). DCs were then washed extensively, lysed and
cell-associated HIV p24 antigen was measured. SAMMA at
100 lg/ml blocked DC-mediated HIV capture by 58–99%
depending on the DC donors (Fig. 4a), which correlated with
the eﬀect of SAMMA on DC-mediated HIV transmission
when SAMMA was only present during HIV capture
(Fig. 1b). When DCs were exposed to HIV-1BaL at 4 C in
the absence and presence of SAMMA, no signiﬁcant diﬀerence
was detected, indicating that SAMMA did not aﬀect HIV
binding to DCs (Fig. 4b). Thus, results in Fig. 4a and b suggest
that SAMMA interfered with internalization of HIV by
DCs.
To delineate whether SAMMA blocked DC-mediated HIV
capture by acting on the cell, DCs were pre-incubated with
SAMMA for 1 h at 37 C and washed four times before expo-
sure to HIV-1BaL for 2 h at 4 C (for binding) or 37 C (for
binding and internalization). DCs were then washed four times
with PBS and lysed. Cell-associated HIV p24 antigen was mea-
sured by ELISA. When DCs were pre-treated with SAMMA
and washed before HIV exposure, SAMMA did not block
HIV binding or binding/internalization by DCs (data not
shown and Fig. 4c), suggesting that inhibition of DC-mediated
HIV capture is primarily due to the eﬀect on the virus.0
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fusion
SAMMA eﬀectively blocked DC-mediated HIV transmission
when the inhibitor was present during the co-culture. DC-
mediated HIV transmission to CD4+ cells occurs at a cell–
cell junction referred to as the infectious synapse
[36–38]. The potent anti-HIV activity of SAMMA during the
co-culture led us to investigate the eﬀect of SAMMA on HIV
glycoprotein-mediated cell–cell fusion. HeLa cells stably
expressing Tat protein (HeLa-Tat cells) were transiently trans-
fected with a vector expressing HIVJR-FL envelope glycoprotein
for 48 h. HeLa-Tat cells expressing HIV glycoproteins were
then incubated with SAMMA at 10, 100, and 1000 lg/ml for
1 h at 37 C before addition to TZM cells, indicator cells that
express CD4 and CXCR4 and CCR5 co-receptors and contain
an HIV LTR-driven reporter gene. HIV Tat proteins synthe-
sized in cells expressing HIV glycoproteins activate the HIV
LTR in the indicator cells after cell–cell fusion occurs. The
fusion inhibitor, T-20, at 100 nM was included to ensure the
speciﬁcity of this assay. As expected, T-20, which blocks HIV
trans infection of target cells by HIV-exposed MDDCs [39],
inhibited HIV glycoprotein-mediated cell–cell fusion. SAMMA
at 10 lg/ml inhibited HIV glycoprotein-mediated cell–cell fu-
sion by 47%. A greater inhibitory eﬀect was achieved with
SAMMA at 100 lg/ml (98%) and 1000 lg/ml (>99%)
(Fig. 5a). SAMMA also blocked cell–cell fusion when the do-
nor cells expressed HIV X4 envelope proteins (data not shown).
To ensure inhibition of HIV glycoprotein-mediated cell–cell
fusion by SAMMA was not due to cytotoxicity, HeLa-Tat or
TZM-bl cells were treated with SAMMA at various concentra-
tions for 24 h. Cell viability was determined by MTS assay. No
signiﬁcant diﬀerence in cell viability between cells in the ab-
sence or presence of SAMMA at up to 1000 lg/ml (Fig. 5b
and data not shown), indicating that the inhibitory eﬀect on
cell–cell fusion in Fig. 5a was not due to cytotoxicity.4. Discussion
SAMMA has been shown to be a potential candidate for
topical microbicides because of its broad antimicrobial andControl T-20    10           100 1000no    HeLa
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Fig. 5. SAMMA inhibits HIV glycoprotein-mediated cell–cell fusion. HeLa
were then treated with a fusion inhibitor T-20 or SAMMA at 37 C for 1 h be
CCR5 and containing a luciferase reporter gene driven by HIV LTR. After i
means ± SD of duplicated samples and represent three independent experime
concentrations for 48 h was determined by MTS assay as described in Fig. 3antiviral activities against C. trachomatis, N. gonorrhoeae,
HIV and HSV [20–22]. Importantly, it does not cause cytotox-
icity in many cell lines and primary cells including human
CD4+ T cells and macrophages (Fig. 3, [20]). Here we investi-
gated the eﬀect of SAMMA on DC-mediated HIV transmis-
sion, which is an important initial step in sexual transmission
of HIV. SAMMA is not cytotoxic for DCs and primary acti-
vated CD4+ T cells when present in the culture for 3 days.
SAMMA eﬀectively blocked HIV transmission by DCs when
present during co-culture period. In addition, SAMMA
blocked HIV transmission when it was incubated with HIV-ex-
posed DCs followed by wash-oﬀ before co-culture with target
cells, suggesting its inhibitory eﬀect persists. The observation
that SAMMA suppressed HIV glycoprotein-mediated cell–cell
fusion by greater than 95% suggests one possible mechanism
by which this compound inhibits HIV transfer when present
during the co-culture period. SAMMA is likely to inhibit gly-
coprotein-mediated cell–cell fusion through interfering with
the interaction between HIV glycoprotein and CD4 receptors,
although it remains to be determined whether SAMMA can
block the step of viral fusion.
We demonstrated that SAMMA blocked DC-mediated
HIV-1 transmission by preventing HIV capture by DCs
(Fig. 4). Speciﬁcally, SAMMA aﬀected the step of HIV inter-
nalization [8]. Further studies using speciﬁc inhibitors target-
ing speciﬁc steps such endocytosis or fusion are required to
dissect in detail the mechanism by which SAMMA inhibits
DC-mediated HIV capture. We demonstrated that SAMMA
has a similar inhibitory proﬁle to mannan and greater than
anti-DC-SIGN or anti-CD4 antibodies (Fig. 2a and b), sug-
gesting that inhibition of capture followed by transfer may
be mediated by blocking HIV interactions with other MCLRs
rather than DC-SIGN or CD4. Macrophage mannose-recep-
tors and an unidentiﬁed trypsin-resistant CLR have been
reported to contribute to gp120 binding in MDDCs [33]. It re-
mains to be determined whether SAMMA interferes with HIV
capture by these receptors on the surface of DCs. In addition,
the varying abundance of speciﬁc receptors among diﬀerent
donors may contribute to diﬀerential inhibitory eﬀects of
SAMMA on DC-mediated HIV capture and transmission in
wash-oﬀ settings (Fig. 1b and 4a). The incomplete block ofb
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bation as well as variation in eﬀectiveness with diﬀerent donor
DC supports the use of SAMMA in combination rather than
alone. Nevertheless, our study and previous reports suggest
that several mechanisms are involved in the anti-HIV eﬀect
of SAMMA [20,21].
SAMMA also inhibited HIV transfer from HIV-exposed
DCs to the indicator cells when added following HIV capture
and washed oﬀ before co-culture. The sustained eﬀect on HIV
transfer from HIV-exposed DCs after washing oﬀ has been re-
ported previously with the inhibitors such as CD4-IgG2 and
antimicrobial peptides, although the mechanism is not clear
[39,40]. It is of note that PRO2000, a sulfonated anionic poly-
mer in phase III clinical trials for topical microbicides against
HIV, exhibits a similar inhibitory eﬀect on HIV transmission
from HIV-exposed DCs in the wash-oﬀ setting (Natalia
Teleshova, manuscript submitted). Like CD4-IgG2,
PRO2000 and SAMMA bind to HIV gp120 [21]. Presumably,
residual SAMMA and or persistent eﬀects of SAMMA on
HIV-exposed cells inactivates HIV or alters the formation of
virological synapse [37,38], resulting in the inhibition of HIV
transmission.
In conclusion, our study demonstrates that SAMMA inhib-
ited DC-mediated HIV transmission through blocking DC-
mediated HIV capture and subsequent transfer. SAMMA also
eﬃciently inhibited HIV glycoprotein-mediated cell–cell
fusion, supporting its potential as an anti-HIV topical micro-
bicide in combination with other inhibitors.
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